In July 2011, the Institute of Public Health in Chile (ISPCH – Instituto de Salud Pública de Chile) confirmed that it had sent a project to create a National Medicines Agency (ANAMED – Agencia Nacional de Medicamentos) to the Congress for approval. The new agency is expected to update the regulation of medicines, strengthen ISPCH’s regulatory functions and implement a number of measures to increase the competitiveness of the pharmaceutical industry. The creation of ANAMED is part of President Sebastián Piñera’s National Policy of Medicaments that aims to ensure that medicaments sold in Chile meet efficacy, safety and equivalence standards. The industry believes that the creation of ANAMED could speed up the pharmaceutical registration process. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-chile.html
The Chilean pharmaceutical market is expected to increase by a moderate CAGR in US dollar terms between 2011 and 2016. Chile will be the third smallest pharmaceutical market in the region in 2016, after Cuba and Peru. In per capita expenditure terms, Chile will rank sixth in 2016. Cheap prices and copycat & generic competition are likely to contain the market in local currency terms in the forecast period. In September 2011, the Ministry of Health reported that it had signed an agreement with PAHO/WHO to acquire drugs via the Strategic Fund, also known as the Regional Revolving Fund for Strategic Public Health Supplies.
Laboratorio Chile, Recalcine, Andrómaco, Saval and Bagó are the leading companies. Laboratorio Chile forms part of the Teva group. Recalcine forms part of Corporación Farmacéutica Recalcine (CFR), which launched an IPO in the Chilean Stock Exchange in May 2011. CFR acquired a 50.8% shareholding in the Canadian Uman and a 41.9% shareholding in the Vietnamese Domesco in November 2011. Andrómaco and Saval remain in local hands, whilst Bagó is the subsidiary of the Argentine Bagó group. Some local producers have been acquired in recent years; the Brazilian Eufofarma acquired Volta and Farmaindustria in December 2010; the Spanish subsidiary of the Italian pharmaceutical company Italfarmaco acquired Labomed in July 2009, and the German Fresenius Kabi acquired Sanderson in 2007.
Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles
EXECUTIVE SUMMARY 1
Snapshot: Strategic Espicom Analysis2
Snapshot: Key Data Projections 3
National Institute for Industrial Property6
Intellectual Property Rights6
Customs IP Co-operation Agreement6
Birth Rate 8
Death Rate 8
Infant Mortality 8
Life Expectancy at Birth 8
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 10
Financing Government Expenditure Law14
Health Authority & Management Law14
Health Guarantees System Law 14
Private Health Amendment Law15
People’s Rights & Duties Law15
REGULATORY AFFAIRS 21
NATIONAL REGULATORY BODIES21
PHARMACEUTICAL REGISTRATION 22
PRICING & REIMBURSEMENT 25
DISTRIBUTION CHANNELS 27
Farmacias Cruz Verde29
MARKET ANALYSIS 31
Balance of Trade46
COMPANY INTELLIGENCE 49
Fresenius Kabi – Sanderson49
Italfarmaco – Labomed50
Teva - Laboratorio Chile50
Instituto Sanitas 53
OTC PHARMACEUTICALS 56
MARKET SIZE 56
GENERIC PHARMACEUTICALS 57
For more information kindly visit :
The Pharmaceutical Market : Chile
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
The Pharmaceutical Market : Chile